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Abstract
Objective: The 2002 CDC guidelines for the prevention
of perinatal group B streptococcus (GBS) stipulate that
vancomycin is reserved for penicillin-allergic women at
high risk for beta-lactam anaphylaxis with resistance to
clindamycin or erythromycin. Our objective was to eval-
uate practitioner adherence to these guidelines.
Methods: This is a retrospective chart review of patients
admitted to labor and delivery who received vancomycin
for GBS prophylaxis from January 1st, 2005 to June 1st,
2007. Identification and documentation of allergic reac-
tions to beta lactams and performance of GBS sensitiv-
ities at the time of screening were recorded.
Results: Eighty-seven patients reporting a penicillin aller-
gy received vancomycin during labor. In 71 patients
screened at 35–37 weeks, sensitivities were not per-
formed for 55 patients, of which 10 reported an anaphy-
lactic-like reaction to penicillin. Of 15 patients who had
sensitivities performed at the time of screening and were
resistant to clindamycin and/or erythromycin, only two
patients, however, described an anaphylactic-like reac-
tion to penicillin. Fourteen patients received vancomycin
due to an unknown GBS status at -35 weeks of ges-
tation and only three patients from this group reported
an anaphylactic-like reaction to penicillin. There were
deviations from the CDC protocol in 82 (94%) of 87
patients who received intrapartum vancomycin there
were deviations in the CDC protocol.
Conclusion: Most patients receiving intrapartum vanco-
mycin for perinatal GBS prophylaxis either did not have
a culture with sensitivities performed at the time of GBS
screening due to a history of anaphylactic-like reactions
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to penicillin or received vancomycin for a mild or
unknown allergy. Physician adherence to the CDC guide-
lines with regards to the use of vancomycin is far from
optimal.
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Introduction
Due to increasing microbial resistance to antibiotics and
its threat to public health and safety, adherence to the
appropriate use of antibiotics in daily practice is needed
by all practitioners. In obstetrics, the use of intrapartum
antibiotics to prevent perinatal group B streptococcus
(GBS) transmission has increased significantly since the
center for disease control (CDC) issued revised guide-
lines for intrapartum antibiotic prophylaxis for GBS car-
riers in 2002 which in turn, has led to a 33% decrease
in the incidence of early onset neonatal GBS disease w5x.
Penicillin is the preferred antibiotic for intrapartum pro-
phylaxis in those women who do not report an allergy to
it or its analogues. A first generation cephalosporin, cefa-
zolin, should be administered to women who report a
history of penicillin allergy that is not manifested by
immediate hypersensitivity reactions such as anaphylax-
is, angioedema, or urticaria. Cephalosporins can be con-
sidered for patients with a penicillin allergy since patients
with allergic-like events associated with penicillin have
a low risk of anaphylaxis with cephalosporin use
(-0.001%) w1x. Vancomycin should, therefore, be
reserved only for penicillin-allergic women at high risk for
anaphylaxis when clindamycin and erythromycin are not
options due to documented resistance.
The purpose of this study was to assess the degree of
clinical adherence to these guidelines at our institution
regarding the use of vancomycin to prevent perinatal
GBS transmission.
Materials and methods
A review of pharmacy records identified all patients admitted to
the labor and delivery unit at our hospital who received intra-
venous vancomycin for GBS prophylaxis from 1 January 2005
to 1 June 2007. The prenatal and hospital records of these
patients and their neonates were reviewed. Identification and
documentation by obstetric providers of allergic reactions to
beta lactams at the time of screening, and in labor and delivery,
and availability of clindamycin and erythromycin sensitivities at
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Table 1 Characteristics of 87 patients with reported penicillin
allergy who received intravenous vancomycin for the prevention
of perinatal group B streptococcal (GBS) disease.
Patient characteristics Number of
patients
Preterm labor patients 14
Anaphylactic-like reaction 3
Non-anaphylactic-like reaction 11*
Term patients 73
Not screened (due to history of GBS) 2*
Anaphylactic-like reaction with documented 2
resistance to clindamycin and/or erythromycin
Anaphylactic-like reaction with no sensitivity 10*
testing
Non-anaphylactic-like allergic reaction with no 45*
sensitivities
Non-anaphylactic-like allergic reaction with 13*
documented resistance to clindamycin
and/or erythromycin
Non-anaphylactic-like allergic reaction with no 1*
antibiotic resistance on sensitivity testing
*Deviations from CDC protocol – 82 patients (94%).
the time of admission to labor and delivery were recorded. The
study was approved by our Institutional Review Board.
Results
During the study period, a total of 12,534 deliveries took
place in our institution. The overall carrier rate for GBS
in our population ranged from 16% to 20% per year dur-
ing the study period. A total of 87 patients, who reported
an allergic reaction to penicillin, received intravenous
vancomycin for the purpose of GBS prophylaxis during
labor. All 87 patients received regular prenatal care and
were a combination of either service or private patients.
A total of 32 different attendings were involved in the care
of these patients.
Table 1 describes the clinical scenarios of all 87
patients who received vancomycin. Of the 87 patients,
no patients had GBS bacteriuria during pregnancy or a
prior neonate with invasive GBS disease. Two patients
who received vancomycin and denied anaphylactic-like
reactions to penicillin were inappropriately not screened
during the current pregnancy due to a history of GBS
colonization in a prior pregnancy. Of the 71 (82%)
patients who were screened, 12 patients had a docu-
mented anaphylactic-like reaction to penicillin thereby
calling for a culture and sensitivity to clindamycin or
erythromycin to be obtained. However, in only two of
these 12 patients were culture and sensitivity performed.
The remaining 59 (68%) patients, who had no docu-
mented history of anaphylactic-like reactions to penicillin,
were candidates to receive cefazolin in labor but instead,
received vancomycin. Cultures and sensitivities were,
therefore, not warranted on 14 patients.
In labor, vancomycin was appropriately administered to
2 (2.3%) patients with GBS colonization at 35–37 weeks
with a history of anaphylactic-like reactions to penicillin
and evidence of resistance to clindamycin and/or eryth-
romycin. Another 3 (3.4%) patients appropriately
received vancomycin due to a history of anaphylactic-
like reactions to penicillin and unknown GBS status at
the time of labor. In another 10 patients who reported a
severe allergy, vancomycin was ultimately required
because sensitivities were not done at the time of
screening. Seventy (80%) patients with no documenta-
tion of anaphylactic-like reactions to penicillin received
vancomycin, and another 10 may have been candidates
for clindamycin if cultures had been obtained at the time
of screening. No adverse events were noted with the use
of vancomycin in our study cohort.
Discussion
There were deviations from the CDC protocol in 82 (94%)
out of the total number of patients who received van-
comycin for GBS prophylaxis in our study cohort.
Chemoprophylaxis for the prevention of neonatal GBS
disease can prevent most cases of early onset neonatal
GBS disease. Although obstetric patients receive antibi-
otics for this indication, the choice of antibiotics is not
always consistent with the CDC guidelines. In a recent
retrospective cohort study of GBS positive, penicillin
allergic patients, adherence to the 2002 CDC guidelines
for intrapartum GBS prophylaxis was far from optimal w3x.
The authors addressed specific issues such as choosing
an appropriate antibiotic as specific areas that need
improvement. In our study group, only 5 (6%) of the
patients who received vancomycin met strict criteria for
its administration for the purpose of GBS chemoprophy-
laxis. Another 10 who reported an anaphylactic-like
reaction to penicillin were appropriately prescribed
vancomycin in labor, but may have been candidates for
clindamycin or erythromycin if sensitivity testing had
been performed at the time of screening. In this cohort
of patients, an initial deviation in the CDC protocol (such
as not screening or not performing a culture) led to
further downstream deviations in choice of antibiotic
for chemoprophylaxis.
Patients are sometimes unsure about their penicillin
allergy and cannot clarify their exact reaction. This, in
turn, may lead to prescribing of an antibiotic that is unre-
lated to the family of penicillins to avoid the possibility of
a severe allergic reaction intrapartum. It is true, however,
that self-reporting of penicillin allergy is often inaccurate.
One study reported that up to 89% of pregnant patients
who report a penicillin allergy at the time of GBS screen-
ing, have negative skin testing to penicillin and are can-
didates for narrow spectrum antibiotic treatment for GBS
prophylaxis w4x.
Vancomycin-resistant enterococci (VRE) were first
reported in 1986. The primary inciting factor identified at
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that time was likely the use of oral vancomycin for treat-
ing antibiotic-associated diarrhea in hospitals w2x. Anti-
biotics that are inactive against enterococci, such as the
cephalosporins and vancomycin, favor colonization with
high levels of VRE in the stool. The judicious use of van-
comycin may limit the emergence and spread of VRE
within hospitals. Although enterococcus is rarely reported
to cause perinatally acquired neonatal infections, it is
commonly isolated from women with post-cesarean
endometritis and wound infections w6x. In this population,
the inappropriate use of vancomycin could lead to
increased incidence of VRE and failure of empirical treat-
ment with vancomycin for such postpartum infections.
Limitations of vancomycin use remains at the corner-
stone of the efforts to limit the spread of vancomycin
resistant organisms. An effort by all practitioners to
adhere to the CDC guidelines, in which narrow spectrum
antibiotics should be used as first line prophylaxis if pos-
sible, is critical. Based on our data, significant improve-
ments are needed. Further studies are warranted on the
possible maternal and neonatal effects of vancomycin,
such as increasing emergence of GBS bacterial resis-
tance as well as differences in maternal and neonatal
outcomes with the use of vancomycin compared to other
antibiotics, when the adherence to the CDC antibiotic
protocol for the prevention of perinatal GBS is not
optimal.
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